Inhibikase Therapeutics, Inc. Operating Income Loss

• Inhibikase Therapeutics, Inc. showed a decrease of -81.8% in Operating Income Loss from 2024 to 2025.
• This data is from Inhibikase Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Inhibikase Therapeutics, Inc.'s Operating Income Loss has declined by 1,744.0%.
• Historical annual values: Fiscal year 2025: -$51.97 million | Fiscal year 2024: -$28.59 million | Fiscal year 2023: -$20.09 million | Fiscal year 2022: -$18.13 million | Fiscal year 2021: -$14.77 million | Fiscal year 2020: -$2.82 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026